MARTINI® Asti Celebrates 150th Anniversary With Sustainability Milestone
15.7.2021 15:04:00 EEST | Business Wire | Press release
After decades spent pioneering sustainable practices in the vineyards of northwest Italy, MARTINI, the world’s number one Italian sparkling wine and vermouth from family-owned Bacardi, is proud to announce that all its Asti grape suppliers are on track to being certified sustainable in 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210715005597/en/
The MARTINI Santo Stefano Belbo winery, located in the heart of the Asti region and responsible for producing 30% of all the grape ‘must’ (grape juice) for MARTINI Asti, was recently certified sustainable by Equalitas, the most comprehensive sustainability standard in Italian wine making, following an audit by certification body, Valoritalia. Of the remaining 70%, more than two-thirds of the grape must suppliers – cooperatives representing hundreds of small grape growers – have also been certified sustainable by Equalitas with the remainder on track to be certified this year. (Photo: Business Wire)
The timing could not be more perfect. As Bacardi celebrates this major sustainability milestone, it’s also celebrating 150 years since Martini & Rossi produced its first samples of ‘moscato spumante d’Asti’ to meet demand from customers around the world back in 1871.
The MARTINI Santo Stefano Belbo winery, located in the heart of the Asti region and responsible for producing 30% of all the grape ‘must’ (grape juice) for MARTINI Asti, was recently certified sustainable by Equalitas, the most comprehensive sustainability standard in Italian wine making, following an audit by certification body Valoritalia. Of the remaining 70%, more than two-thirds of the grape must suppliers – cooperatives representing hundreds of small grape growers – have also been certified sustainable by Equalitas with the remainder on track to be certified this year.
Together with the recent announcement that the 10 botanicals used to create BOMBAY SAPPHIRE® will be certified sustainable in 2021, this news is another major step towards Bacardi achieving its 2025 goal of sourcing 100% of its key ingredients from sustainably certified suppliers.
It was back in 1987 that, in true pioneering style, MARTINI established a center dedicated to sustainable business practices called L'Osservatorio MARTINI – the MARTINI Observatory. Located in the heart of the region and led by a local agronomist expert in the cultivation of vineyards, L'Osservatorio MARTINI has introduced many sustainability practices to the region – from advising on natural ways to manage pests through to integrated viticulture, looking at the balance of what is grown in the microclimates of the Asti region.
“There is a deep connection between MARTINI, the land and the people – it’s a solid foundation for making quality wine,” said Giorgio Castagnotti, Director of the MARTINI Operations Center in Pessione, Italy. “We have worked closely with the same farming communities growing the finest Moscato grapes in the same beautiful hills for generations – in fact for the last 150 years – and we want to continue to do so for generations to come. It’s always made sense then for us support our grape growers through our sustainability initiatives.”
The steep, sun-drenched hills of Asti in the heart of the Piedmont region of Italy, are the ideal growing environment for the Moscato Bianco grape, and have a DOCG designation, the highest quality level for Italian wines. Expertly harvested in late summer by more than 200 small growers – known collectively as the Conferenti – the grapes are pressed quickly to capture the desired natural flavors in the fresh juice called ‘must’. Through fermentation, this ‘mosto’ becomes the basis of MARTINI Asti’s delicate flavors including notes of peach, sweet wild sage, fresh pear and pineapple.
Stefano Stefanucci, Director of Equalitas, said: “This is a big achievement for MARTINI. Equalitas only works with third-party auditors who are experts with a deep knowledge of the wine sector and the certification process is wholly holistic. Equalitas embraces three sustainability pillars – environmental, ethical and economical – and takes into consideration everything from a winery’s carbon footprint and water consumption through to fair commercial terms for farmers and good social practices including training and welfare.”
Victoria Morris, Global VP MARTINI, added: “Being a family-owned company genuinely makes a difference to the way Bacardi approaches sustainability. We are committed to doing the right thing for the environment, for our suppliers and for their communities for the long term. I am incredibly proud of Giorgio and his team. They are masters of their craft and have reached a new milestone in the long history of MARTINI. It’s the perfect way to toast 150 years of MARTINI Asti!”
Find out more about the sustainability commitments of Bacardi and its vision to become the most environmentally responsible global spirits company at https://www.bacardilimited.com/corporate-responsibility/environment/.
Always drink responsibly.
About MARTINI
One of the most iconic brands in the world, MARTINI® is the leading name in Italian winemaking and a purveyor of the highest quality aromatized and sparkling wines. The award- winning, vibrant and bittersweet taste of the MARTINI range is the result of secret blends of more than 40 botanicals sourced from the finest locations across the globe. First created in 1863 in Turin, Italy, the MARTINI portfolio today includes: MARTINI Fiero, MARTINI Riserva Speciale Rubino, MARTINI Riserva Speciale Ambrato, MARTINI Riserva Speciale Bitter, MARTINI Bianco, MARTINI Rosato, MARTINI Rosso, MARTINI Extra Dry, MARTINI Asti, MARTINI Prosecco and MARTINI Rosé Extra Dry. For more information, please visit www.martini.com.
MARTINI and the ball & bar logo are trademarks. MARTINI is part of the portfolio of Bacardi Limited, headquartered in Hamilton, Bermuda. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited.
About Bacardi
Bacardi Limited, the largest privately held spirits company in the world, produces and markets internationally recognized spirits and wines. The Bacardi Limited brand portfolio comprises more than 200 brands and labels, including BACARDÍ® rum, GREY GOOSE® vodka, PATRÓN® tequila, DEWAR’S® Blended Scotch whisky, BOMBAY SAPPHIRE® gin, MARTINI® vermouth and sparkling wines, CAZADORES® 100% blue agave tequila, and other leading and emerging brands including WILLIAM LAWSON’S® Scotch whisky, ST-GERMAIN® elderflower liqueur, and ERISTOFF® vodka. Founded nearly 160 years ago in Santiago de Cuba, family-owned Bacardi Limited currently employs more than 7,000, operates production facilities in 11 countries, and sells its brands in more than 170 countries. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Visit www.bacardilimited.com or follow us on Twitter, LinkedIn or Instagram.
About Equalitas
Equalitas Srl was founded in 2015 by Federdoc ed Unione Italiana Vini, with a view to building on the technical and cultural achievements of a movement of stakeholders committed to developing wine sustainability, in support of the Forum for Wine Sustainability and the UIV-Tergeo project. The initial partnership was later completed and strengthened by the participation of CSQA Certificazioni, one of the leading agrifood certification bodies in Italy; Valoritalia, the first Wine Denomination of Origin certifying body; Gambero Rosso, Italy’s largest multimedia publisher specializing in food and wine; and 3AVino, a financial company targeting the wine-growing industry. A broad set of skills and expertise that can ensure a comprehensive and integrated approach to sustainability, from the point of view of its economic, social and environmental components. Visit www.equalitas.it.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210715005597/en/
Contact information
Andrew Carney, Communications Director Europe, Australia & New Zealand, Bacardi, acarney@bacardi.com
Jessica Merz, Global Head of Corporate Communications, Bacardi, jmerz@bacardi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
